Life Technologies’ Manohar Furtado, Ph.D. Appointed to National Biodefense Science Board
Board Will Advise Health and Human Services on Bioterrorism, Emergency Preparedness
CARLSBAD, Calif. – February 14, 2012 – -- Life Technologies Corporation (NASDAQ:LIFE - News) today announced that Manohar R. Furtado, Ph.D., vice president of research and development, has been appointed to National Biodefense Science Board. Members of this Board advise the federal Health and Human Services (HHS) Secretary on issues related to bioterrorism and other public health emergencies.
“Manohar is widely recognized as a ‘go to’ leader in shaping public health responses during emergency situations,” said Mark Stevenson, president and chief operating officer at Life Technologies. “During the H1N1 outbreak in 2009, Manohar led Life’s R & D team that collaborated with the CDC (Centers for Disease Control and Prevention) team that led to the first FDA-cleared test for the virus using CDC’s assay and Life’s 7500 DX instrument.”
In 2004, Furtado led the R & D team that worked with USAMRIID (U.S. Army Medical Research Institute of Infectious Diseases) and others to implement anthrax detection tests at the United States Postal Service. He has also collaborated in developing guidelines for biothreat detection and molecular diagnostic testing with organizations including the ATCC, Clinical Laboratory Standards Institute and the Association for Molecular Pathology.
“I look forward to applying my experience with infectious diseases and rapid assay development to enable rapid, thorough responses to outbreaks and biological threats,” said Furtado. “It will be an honor to serve on the National Biodefense Science Board and contribute to protecting public health.”
Furtado received his Ph.D. at Pune University in India and completed a post-doctoral fellowship in molecular virology at Northwestern University Medical School. He served on the faculty at Northwesterns’ R.H. Lurie Comprehensive Cancer Center and was director of the clinical virology and retrovirology laboratories at Northwestern Memorial Hospital. Furtado has more than 70 publications in peer-reviewed journals.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, Gibco, Ambion, Molecular Probes and Taqman products. Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com. Follow Life Technologies on Twitter @LIFECorporation and on Facebook.
Life Technologies’ Safe Harbor Statement
This press release includes forward-looking statements about Life Technologies’ anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.